FDA Approves Acalabrutinib with Venetoclax for CLL or SLL By Ogkologos - March 4, 2026 3 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AMPLIFY study Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer December 19, 2025 11-Year-Old Cancer Survivor With One Leg Dances With Professional Tapper Lord... October 30, 2019 Inhibition of GDF-15 with Ponsegromab Results in Increased Weight Gain and... September 20, 2024 Olivia Newton-John Talks About Her Use Of Medical Cannabis During Cancer... May 28, 2019 Load more HOT NEWS Opinion: ‘We’re making headway, but we can’t be complacent’ Stress-Induced Immune Changes May Help Cancer Spread Steroids May Limit the Effectiveness of Immunotherapy for Brain Cancer Alectinib Approved as an Adjuvant Treatment for Lung Cancer
